RhoVac Beheer

Beheer criteriumcontroles 2/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Lars Hedbys

Algemeen directeur

SEK 191.6k

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	less than a year
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	geen gegevens
Gemiddelde ambtstermijn bestuur	4yrs

Recente managementupdates

Recent updates

CEO

Lars Hedbys (65 yo)

less than a year

Tenure

SEK 191,610

Compensatie

Mr. Lars Hedbys, Ph. D., served as Director at Hamlet Pharma AB (publ) until 2022. He serves as Independent Chairman of the Board of Directors at Scandinavian ChemoTech AB (publ) since 2020. He serves as D...

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Lars Hedbys	Acting CEO & Director	8yrs	SEK 191.61k	geen gegevens
Per Straten	Scientific Advisor & Co-Founder	no data	geen gegevens	geen gegevens
Lars Hockenstrom	Director	3yrs	SEK 191.61k	geen gegevens
Cristina Glad	Director	8yrs	SEK 160.69k	geen gegevens
Gunnar Gardemyr	Chairman	5yrs	SEK 383.22k	geen gegevens
Georg Holländer	Scientific Advisory Board	2.3yrs	geen gegevens	geen gegevens
Anne Ridley	Member of Scientific Advisory Board	2.9yrs	geen gegevens	geen gegevens
Per-Anders Abrahamsson	Scientific advisor	no data	geen gegevens	geen gegevens
Klaus Brasso	Scientific Advisor	no data	geen gegevens	geen gegevens

4.0yrs

Gemiddelde duur

65.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van RHOVAC wordt beschouwd als ervaren (gemiddelde ambtstermijn 4 jaar).

RhoVac Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

No independent directors

RhoVac AB Announces Resignation of Anders Ljungqvist as Board Member

RhoVac AB Appoints Lars Hedbys as Acting CEO, Starting from September 1, 2022

Rhovac AB Announces Resignation of Anders Månsson as CEO

No independent directors

Recent updates

Chosa ApS completed the acquisition of RhoVac AB (NGM:RHOVAC) from M2 Asset Management AB (publ) and others in a reverse merger transaction.

RhoVac AB to Report Fiscal Year 2022 Results on Feb 10, 2023

No independent directors

RhoVac AB Announces Resignation of Anders Ljungqvist as Board Member

RhoVac AB to Report Q3, 2022 Results on Nov 11, 2022

RhoVac AB Appoints Lars Hedbys as Acting CEO, Starting from September 1, 2022

RhoVac AB to Report Q2, 2022 Results on Aug 26, 2022

Rhovac AB Announces Resignation of Anders Månsson as CEO

RhoVac AB's Phase IIb Study in Prostate Cancer , BRaVac, Failed to Meet Its Primary Endpoint

Pre-Clinical Findings Support the Potential Use of RhoVac AB's Drug Candidate, Onilcamotide, Across Several Cancers

No independent directors

RhoVac AB Announces Scientific Publication Supports its Cancer Treatment Method

We're Keeping An Eye On RhoVac's (NGM:RHOVAC) Cash Burn Rate

RhoVac AB Announces Another Clean Interim Safety Review of Clinical Phase IIb Study in Prostate Cancer

RhoVac's Market Research Shows Great Potential for A Cancer Vaccine Preventing Recurrence of Metastatic Disease in Multiple Cancers

Rhovac Announces the Completion of Patient Recruitment for the Bravac Clinical Phase Iib Study of Rv001 in Prostate Cancer

RhoVac (NGM:RHOVAC) Is In A Good Position To Deliver On Growth Plans

RhoVac AB Receives Approval to Initiate a Long-Term Follow-Up of Clinical Phase I/II Patients

Is RhoVac (NGM:RHOVAC) In A Good Position To Deliver On Growth Plans?

Rhovac AB Announces the Initiation of First New US Clinic in Company's Phase IIb Study

New 90-day low: kr21.00

Global Covid-19 Vaccination Roll-Out Causes Delay to Rhovac's Phase IIb Study

RhoVac AB Announces First patient in treatment in RhoVac's clinical phase IIb study in United Kingdom

We Think RhoVac (NGM:RHOVAC) Can Easily Afford To Drive Business Growth

New 90-day high: kr21.15

RhoVac's Prostate Cancer Drug Candidate, RV001, is granted Fast Track Designation by the FDA

Rhovac AB Announces That Positive Results from Rhovac's Clinical Phase I/Ii Study Published in Journal of Immunotherapy of Cancer

New 90-day low: kr16.44

RhoVac AB Announces Covid-19 pandemic affecting RhoVac's clinical phase IIb study

New 90-day high: kr20.65

RhoVac AB Announces First Patient in Treatment in Rhovac's Clinical Phase IIb Study in Sweden

RhoVac AB to Report Q2, 2020 Results on Aug 28, 2020

New 90-day high - kr16.98

CEO

Tenure

Compensatie

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd